Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study

Matt D T Hitchings, Otavio T Ranzani, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Maria Almiron, Rodrigo Said, Ryan Borg, Wade L Schulz, Roberto Dias de Oliveira, Patricia Vieira da Silva, Daniel Barros de Castro, Vanderson de Souza Sampaio, Bernardino Cláudio de Albuquerque, Tatyana Costa Amorim Ramos, Shadia Hussami Hauache Fraxe, Cristiano Fernandes da Costa, Felipe Gomes Naveca, Andre M Siqueira, Wildo Navegantes de Araújo, Jason R Andrews, Derek A T Cummings, Albert I Ko, Julio Croda, Matt D T Hitchings, Otavio T Ranzani, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Maria Almiron, Rodrigo Said, Ryan Borg, Wade L Schulz, Roberto Dias de Oliveira, Patricia Vieira da Silva, Daniel Barros de Castro, Vanderson de Souza Sampaio, Bernardino Cláudio de Albuquerque, Tatyana Costa Amorim Ramos, Shadia Hussami Hauache Fraxe, Cristiano Fernandes da Costa, Felipe Gomes Naveca, Andre M Siqueira, Wildo Navegantes de Araújo, Jason R Andrews, Derek A T Cummings, Albert I Ko, Julio Croda

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread Gamma variant transmission has not been reported.

Methods: We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where the Gamma variant accounted for 86% of genotyped SARS-CoV-2 samples at the peak of its epidemic. We performed an early analysis of effectiveness following administration of at least one vaccine dose and an analysis of effectiveness of the two-dose schedule. The primary outcome was symptomatic SARS-CoV-2 infection.

Findings: For the early at-least-one-dose and two-dose analyses the study population was, respectively, 53,176 and 53,153 HCWs residing in Manaus and aged 18 years or older, with complete information on age, residence, and vaccination status. Among 53,153 HCWs eligible for the two-dose analysis, 47,170 (89%) received at least one dose of CoronaVac and 2,656 individuals (5%) underwent RT-PCR testing from 19 January, 2021 to 13 April, 2021. Of 3,195 RT-PCR tests, 885 (28%) were positive. 393 and 418 case-control pairs were selected for the early and two-dose analyses, respectively, matched on calendar time, age, and neighbourhood. Among those who had received both vaccine doses before the RT-PCR sample collection date, the average time from second dose to sample collection date was 14 days (IQR 7-24). In the early analysis, vaccination with at least one dose was associated with a 0.50-fold reduction (adjusted vaccine effectiveness (VE), 49.6%, 95% CI 11.3 to 71.4) in the odds of symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the first dose. However, we estimated low effectiveness (adjusted VE 36.8%, 95% CI -54.9 to 74.2) of the two-dose schedule against symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the second dose. A finding that vaccinated individuals were much more likely to be infected than unvaccinated individuals in the period 0-13 days after first dose (aOR 2.11, 95% CI 1.36-3.27) suggests that unmeasured confounding led to downward bias in the vaccine effectiveness estimate.

Interpretation: Evidence from this test-negative study of the effectiveness of CoronaVac was mixed, and likely affected by bias in this setting. Administration of at least one vaccine dose showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic Gamma variant transmission. However, the low estimated effectiveness of the two-dose schedule underscores the need to maintain non-pharmaceutical interventions while vaccination campaigns with CoronaVac are being implemented.

Funding: Fundação Oswaldo Cruz (Fiocruz); Municipal Health Secretary of Manaus; Fundação de Vigilância em Saúde do Amazonas.

Keywords: Brazil; COVID-19; CoronaVac; P.1 variant; case-control study; test-negative study.

Conflict of interest statement

We declare no competing interests.

© 2021 The Authors. Published by Elsevier Ltd.

Figures

Figure 1
Figure 1
SARS-CoV-2 infections and vaccination coverage amongst 67,718 healthcare workers (HCW) in Manaus, Brazil between 1 October 2020 to 13 April 2021. Daily RT-PCR confirmed SARS-CoV-2 infections with and without COVID-19 symptoms are shown as red and blue bars, respectively. Green and blue lines depict the daily cumulative proportion of the 67,718 HCWs who received respectively, a first and second dose of a COVID-19 vaccine. The grey shade denotes the study period, which began with the initiation of the vaccine campaign on 19 January, 2021 and ended on 25 March, 2021 for the early analysis and on 13 April, 2021 for the two-dose analysis.
Figure 2
Figure 2
Flowchart for case and control selection.

References

    1. Fujino T, Nomoto H, Kutsuna S, et al. Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan. Emerg Infect Dis. 2021;27 doi: 10.3201/eid2704.210138.
    1. Naveca FG, Nascimento V, de Souza VC, et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med. 2021 doi: 10.1038/s41591-021-01378-7. published online May 25.
    1. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021 eabh2644.
    1. Lineage P.1. (accessed April 6, 2021).
    1. World Health Organization-WHO. Weekly epidemiological update - 27 January 2021. (accessed April 6, 2021).
    1. . COVID-19 data in Brazil. (accessed April 4, 2021).
    1. Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021 S0092867421004281.
    1. Wang G-L, Wang Z-Y, Duan L-J, et al. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization. N Engl J Med. 2021 NEJMc2103022.
    1. Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021 S0092867421003676.
    1. NGS-SA, COMMIT-KZN Team. Cele S, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021 doi: 10.1038/s41586-021-03471-w. published online March 29.
    1. Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe. 2021
    1. Souza WM, Amorim MR, Sesti-Costa R, et al. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021 doi: 10.1016/S2666-5247(21)00129-4.
    1. Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. The Lancet Infectious Diseases. 2021 S1473309921002875.
    1. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192.
    1. Bueno SM, Abarca K, González PA, et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. Infectious Diseases (except HIV/AIDS), 2021 doi:10.1101/2021.03.31.21254494.
    1. Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Journal. 2021 doi: 10.2139/ssrn.3822780.
    1. Strategic Advisory Group of Experts on Immunization - SAGE (WHO). Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. 2021; published online May 24. .
    1. Verani JR, Baqui AH, Broome CV, et al. Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017;35:3295–3302.
    1. Verani JR, Baqui AH, Broome CV, et al. Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. Vaccine. 2017;35:3303–3308.
    1. Brazilian Ministry of Health. POPULAÇÃO RESIDENTE - ESTUDO DE ESTIMATIVAS POPULACIONAIS POR MUNICÍPIO, IDADE E SEXO 2000-2020 - BRASIL. Estimativas preliminares elaboradas pelo Ministério da Saúde/SVS/DASNT/CGIAE. (accessed April 3, 2021).
    1. Brazilian Institute of Geography and Statistics - IBGE. 2010 Population Census. (accessed April 27, 2021).
    1. Fundação de Vigilância em Saúde do Amazonas. BOLETIM DIÁRIO COVID-19 NO AMAZONAS 2/4/2021. (accessed April 3, 2021).
    1. Buss LF, Prete CA, Abrahim CMM, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021;371:288–292.
    1. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet. 2021;397:452–455.
    1. Brazilian Ministry of Health. Epidemiologic Surveillance Guide. National Emergency of Public Health Concern due to the COVID-19 disease. (accessed May 25, 2021).
    1. Jennison C, Turnbull BW. Chapman & Hall/CRC; Boca Raton: 2000. Group sequential methods with applications to clinical trials.
    1. Breslow NE, Day NE, Breslow NE. International Agency for Research on Cancer; Lyon: 2000. The analysis of case-control studies, 8. reimpression.
    1. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol. 2016;184:345–353.
    1. Ranzani OT, Bastos LSL, Gelli JGM, et al. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. The Lancet Respiratory Medicine. 2021;9:407–418.
    1. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197.
    1. Strategic Advisory Group of Experts on Immunization - SAGE (WHO). Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. Report from 29/04/2021. (accessed May 26, 2021).
    1. Ranzani OT, Hitchings M, Dorion M, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. Infectious Diseases (except HIV/AIDS), 2021 doi:10.1101/2021.05.19.21257472.
    1. de Faria E, Guedes AR, Oliveira MS, et al. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report. Infectious Diseases (except HIV/AIDS), 2021 doi:10.1101/2021.04.12.21255308.
    1. Victora C, Castro MC, Gurzenda S, et al. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: Analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine. 2021 doi: 10.1016/j.eclinm.2021.101036.
    1. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021
    1. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021 doi: 10.1038/s41591-021-01325-6. published online April 1.
    1. Lewnard JA, Patel MM, Jewell NP, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology. 2021 doi: 10.1101/2021.01.21.21250258.
    1. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021:n1088.
    1. Moustsen-Helms IR, Emborg H-D, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. Epidemiology. 2021 doi: 10.1101/2021.03.08.21252200.
    1. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397:1204–1212.
    1. Vahidy FS, Pan AP, Ahnstedt H, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS One. 2021;16
    1. Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021:1–10. doi: 10.1016/S0140-6736(21)01429-X.
    1. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021:1–11. doi: 10.1056/NEJMoa2107715.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi